NEWS 2022

A first clinical study enrolling 372 pregnant women has been completed, showing 100% concordance of our genetic analysis on circulating trophoblasts with the data generated by standard of care prenatal diagnosis.

NEWS 2023

A second clinical study enrolling 2000 pregnant women is in progress. In this study we are comparing microarray data obtained by standard of care prenatal diagnosis with data generated on the same patients with our CB-NIPT test.


30 Pasir Panjang Road,
Mapletree Business City, #08-32
Singapore 117440

Via G. Di Vittorio, 21b/3,
40013 Castel Maggiore
© 2019 | Menarini Biomarkers Singapore (MBS) is a company fully owned by Menarini Group  |  Privacy Policy  |  Cookie Policy